Filing Summary
Business Context and Reporting Period
Adlai Nortye Ltd., a Cayman Islands foreign private issuer, filed this Form 6-K for the month of May 2024. The report was filed on May 23, 2024, under Commission File Number 001-41773. The company files annual reports on Form 20-F.
Financial and Operating Metrics
The filing cover page does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Changes and Corporate Developments
- The filing furnishes a press release announcing that the company would present data on the combination of AN0025 and definitive chemoradiotherapy at ASCO 2024.
- The filing also furnishes Adlai Nortye’s May 2024 corporate presentation.
Outlook, Risks, and Unusual Items
The provided filing text does not include the contents of the press release or corporate presentation. Accordingly, it does not provide clear information on clinical results, guidance, management commentary, risks, contingencies, or unusual items beyond the planned ASCO 2024 presentation.
Key Facts to Verify
- Review Exhibit 99.1 for the detailed AN0025 and definitive chemoradiotherapy data, study design, endpoints, safety findings, and management commentary.
- Review Exhibit 99.2 for the company’s pipeline, development strategy, financial position, expected milestones, and risk disclosures.
- Verify any forward-looking statements and associated risks in the furnished exhibits.